Target Engagement and Cognitive Outcomes of Anti‐Amyloid Immunotherapies in Early‐Onset Alzheimer's Disease: First Report from the LEADS Study

Abstract

Background: In clinical trials, monoclonal antibodies targeting Aβ pathology have shown strong target engagement, resulting in rapid Aβ clearance and a deceleration in rate of clinical decline.

The paper